Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs
1 min read
Summary
Pharmaceutical company Eli Lilly is suing four telehealth firms for allegedly selling unlicensed copies of its Zepbound and Mounjaro diabetes treatments.
The drugs, known as GLP-1s, are seen as being highly effective in treating diabetes and obesity, but have recently faced supply issues.
This has led compounding pharmacies to start offering unlicensed, unapproved and potentially unsafe versions of the drugs, which can be purchased via telehealth services, direct-to-patient pharmacies and through other online medical platforms.
Lilly is arguing that the varieties on offer are unsuitable for mass production and unsuited to many patients because they are not tailored to individual need in the way that compounded drugs usually are.
The lawsuits name Mochi Health, Fella & Delilah Health, Willow Health and Henry Meds as selling the unlicensed products.
